NASDAQ:ACRS Aclaris Therapeutics Q2 2026 Earnings Report $5.53 -0.11 (-1.95%) Closing price 04:00 PM EasternExtended Trading$5.37 -0.16 (-2.97%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aclaris Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.16Beat/MissBeat by +$0.01One Year Ago EPSN/AAclaris Therapeutics Revenue ResultsActual Revenue$1.63 millionExpected Revenue$1.38 millionBeat/MissBeat by +$246.00 thousandYoY Revenue GrowthN/AAclaris Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsAclaris Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aclaris Therapeutics Earnings HeadlinesAclaris Therapeutics (ACRS): Multiple Catalysts Could Make 2H 2026 A Defining PeriodSeptember 10, 2026 | rttnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.33 Average Price Target from BrokeragesSeptember 10, 2026 | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 15 at 1:00 AM | The Oxford Club (Ad)Critical Survey: Whitehawk Therapeutics (NASDAQ:WHWK) vs. Aclaris Therapeutics (NASDAQ:ACRS)September 9, 2026 | americanbankingnews.comAclaris Therapeutics (NASDAQ:ACRS) Earns Buy Rating from Analysts at Canaccord Genuity GroupSeptember 4, 2026 | americanbankingnews.comAclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comSee More Aclaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email. Email Address About Aclaris TherapeuticsAclaris Therapeutics (NASDAQ:ACRS) (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research programs are centered on potentially addressing conditions in which existing treatments have limited effectiveness or tolerability. Aclaris has developed a pipeline that has included zunsemetinib, an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being studied for inflammatory diseases, and other small-molecule therapies targeting immune and inflammatory pathways. The company has also investigated topical treatments for dermatological conditions, including atopic dermatitis and other skin disorders. Founded in 2012 and headquartered in Wayne, Pennsylvania, Aclaris previously commercialized ESKATA, a topical treatment for raised seborrheic keratoses, before discontinuing the product. The company’s current activities are primarily focused on research, clinical development and advancing its pipeline through clinical testing and potential strategic partnerships.View Aclaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks RiskyCould Dave & Buster’s Capitulation Signal the Bottom Is Finally In?Navan's Strong Quarter Meets an AI Spending Reality Check3 Defense Stocks Riding the High-Energy Laser BoomLightPath’s Defense Pivot Could Send Shares Higher3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
